Tennis is the first major women’s sports league to require genetic testing

The Women’s Tennis Association has introduced a new gender eligibility policy requiring genetic sex testing for all female athletes. The mandate focuses on screening for the SRY gene, which is typically found on the Y chromosome. While proponents argue this protects the women’s category, experts note that the test does not account for the complexities of human biology. Athletes with certain intersex variations may fail this test despite living their entire lives as women.

This move separates the tennis league from most other professional women’s sports organizations, which do not currently require gene screening. Scientists have pointed out that the presence of the SRY gene does not provide a complete picture of an individual’s biological function or hormone production. The policy requires athletes who do not pass the screening to undergo additional medical reviews and provide private health records to prove their eligibility to compete.

Advocacy groups are raising concerns about the privacy implications for all women in the sport. The process forces participants to surrender sensitive genetic and medical data to governing bodies. There are no known transgender women currently on the WTA tour, which has led many observers to focus on the impact this policy has on cisgender women who may have undiagnosed intersex conditions.

Pressure from federal initiatives and international sports standards has influenced this shift in the athletic landscape. While the International Olympic Committee and World Athletics have adopted similar SRY gene requirements for their events, the WTA remains a private entity. The league is currently the only major women's sports organization to implement such a rigorous screening requirement as a condition of participation.